Get the app
USHealthcare

GRAIL, LLC (GRAL)

US · Healthcare · Diagnostics & Research

$79.95+6.44%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$44.7M
Revenue YoY
+25.7%
Net profit
$-110.2M
EPS
$-2.56
EPS estimate
$-2.91
Net margin
-246.7%

EPS came in at -2.56 against a street estimate of -2.91 — a beat of 12.0%.

Key statistics

Market cap
$3.35B
Forward P/E
0.0
P/B
1.33
Book value
$56.93
EPS (TTM)
$-9.69
52-week high
$118.84
52-week low
$39.30
50-day MA
$73.54
200-day MA
$72.66
Beta
3.25

Analyst view

Analysts rate GRAIL, LLC a buy (1 buy, 3 hold, 0 sell out of 4) with an average price target of $77.00.

From the latest earnings call · 2026-08-05

CONFIDENT GRAIL posted 26% revenue growth to $44.7M on 35% volume growth. Galleri detected 6.5× more cancers vs. standard care. FDA AdCom expected fall 2026; approval anticipated early 2027. Samsung $110M investment backs Asian expansion. Q2 2026 U.S. driving volume; NHS organizational changes creating near-term uncertainty but clinician enthusiasm remains high. Samsung partnership to drive Asia expansion starting South Korea. Analysts pressed on AdCom timing and specificity of FDA communication; management reaffirmed expectation but no new public details. Pricing pressure and competitive noise addressed via rigorous data differentiation and sales follow-up. Medicare NCD timing left speculative. 2026-08-05…

Full summary in the app.

Shareholding

Insiders
5.00%
Institutions
86.29%

Largest institutional holders

FundStake
Baker Bros Advisors LP9.02%
Farallon Capital Management, L.L.C.7.28%
BlackRock Inc6.65%
PRIMECAP Management Company4.88%
State Street Corp4.24%
Deep Track Capital, LP4.11%
Sessa Capital, L.P3.85%
Morgan Stanley - Brokerage Accounts3.65%

Recent filings & reports

DocumentDate
Quarterly report · Q2 2026
GRAIL, INC. - FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash & Securities Position: $55.6 million cash + $806.0 mill
2026-08-06
Results announced · Q3 2026
GRAIL Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenue: $44.7 million, up 26% year-over-year • Q2 2026 Galleri Screening R
2026-08-05
Shareholder vote results · Q2 2026
GRAIL, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 18, 2026 • 35,076,394 shares represented (81.7% of 42,916,593 total share
2026-06-22
Board / officer change · Q2 2026
GRAIL, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Dr. Joshua Ofman appointed as Chief Executive Officer effective June 1, 2026 • Annual base salary
2026-06-01
Quarterly report · Q1 2026
GRAIL, Inc. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $69.3 million in cash and cash equivalents; $753.8 million in short-term market
2026-05-07
Results announced · Q2 2026
GRAIL Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total revenue: $40.8 million, up 28% year-over-year • Galleri screening revenue: $39.8 mi
2026-05-05
Proxy statement · Q2 2026
GRAIL, INC. — 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect Steven Mizell and Sarah Krevans as Class II Dire
2026-04-28
Annual report FY2025
GRAIL, INC. - FORM 10-K SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Company: GRAIL, Inc. (Ticker: GRAL, Nasdaq) • Fiscal Year Ended: Decemb
2026-03-12

Readable in the app.

Deals & corporate news

AnnouncementDate
Strategic partnership with Samsung; equity investment and commercialization collaboration
GRAIL, Inc. announced a $110 million private investment from Samsung entities (Samsung C&T and Samsung Electronics Singapore) on October 16, 2025. Samsung will purchase 1,570,308 shares at $
2025-10-16

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for GRAIL, LLC — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.